In accounting, IPR&D (in-process research and development) is an intangible asset recorded on an acquirer’s balance sheet after a business combination, representing the fair value of the target company’s unfinished research projects. When one company buys another, the purchase price has to be spread across everything of value that was acquired. If part of what the buyer paid for is a drug candidate still in clinical trials or a technology still being engineered, that incomplete project gets its own line as an identifiable intangible asset rather than being lumped into goodwill. The treatment matters most in pharmaceuticals, biotech, and technology, where unfinished pipelines often drive the deal.
Why Acquired R&D Gets Different Treatment Than Internal R&D
The sharpest thing to understand about IPR&D is how differently it’s treated from a company’s own ongoing research spending. Under ASC 730, internal R&D is expensed as incurred. A pharmaceutical company spending $2 billion a year on its own drug development runs every dollar through the income statement in the period it’s spent, and nothing appears on the balance sheet to show for it. The reasoning is that most R&D is too uncertain to call an asset.1U.S. Securities and Exchange Commission. 7. Intangible Assets
Acquired IPR&D flips that. When the same company buys another firm whose drug candidates are mid-development, the fair value of those incomplete projects is capitalized as an intangible asset. The logic: a buyer has to allocate the purchase price across everything of value it acquired, and an unfinished project with real commercial potential has value. The buyer paid for it, so it has to be recorded at what it’s worth.
The practical consequence is a reporting gap. Two identical drug candidates at the same stage of development look different on the books depending on how they got there. The one built in-house is invisible on the balance sheet; the one acquired sits there as an asset. Investors reading financial statements from acquisition-heavy companies should keep that asymmetry in mind.
Where IPR&D Fits in Purchase Price Allocation
ASC 805 requires the acquirer to identify and measure every asset and liability of the target at fair value. The total consideration paid is then distributed across tangible assets, identifiable intangibles (customer relationships, trade names, technology, IPR&D), liabilities assumed, and whatever is left over as goodwill.2Deloitte Accounting Research Tool. Deloitte Roadmap – Business Combinations – 4.10 Intangible Assets
For an incomplete R&D project to qualify as IPR&D rather than get absorbed into goodwill, it has to meet the definition of an identifiable asset. That means it either arises from contractual or legal rights or can be separated from the business and sold on its own. It also has to have substance and genuinely be incomplete.
The distinction between IPR&D and goodwill is not cosmetic. Goodwill is never amortized under current GAAP; it sits on the balance sheet and is tested for impairment. IPR&D will eventually either convert to an amortizing asset if the project succeeds or be written off entirely if it fails. Allocating value correctly between the two buckets shifts how the deal ripples through future earnings.
How IPR&D Is Valued
Measuring the fair value of something that doesn’t exist yet as a finished product is hard, and IPR&D measurements almost always land in Level 3 of the ASC 820 fair value hierarchy, the category for valuations relying on unobservable inputs like projected cash flows, discount rates, and probability estimates rather than market prices.3U.S. Securities and Exchange Commission. The Fair Value Measurement Accounting Standard, Codified in ASC 820
Income Approach and the MPEEM
Most valuations use an income-based approach. Valuation specialists project the cash flows the project should generate once commercialized and discount them to present value. The common technique is the Multi-Period Excess Earnings Method, which isolates earnings attributable specifically to the IPR&D asset by subtracting charges for every other asset that contributes to those earnings: working capital, fixed assets, the assembled workforce, and existing technology.
Those deductions are called contributory asset charges and represent the fair return each supporting asset would need to earn if it were rented from a third party. Set them too high and the IPR&D asset is undervalued; set them too low and it is overvalued. In practice they can consume 30 to 60 percent of the gross earnings attributed to the project.
Discount Rates and Probability of Success
The discount rate applied to IPR&D cash flows runs well above a company’s weighted average cost of capital because it has to capture technical, regulatory, and commercial risk. A survey of biotech valuation professionals found average discount rates of roughly 40 percent for early-stage projects, 27 percent for mid-stage, and 20 percent for late-stage assets.
The valuation also has to incorporate a probability-of-success adjustment, quantifying the likelihood the project clears its remaining hurdles, whether that’s a Phase III trial, FDA approval, or final engineering validation. Multiplying projected cash flows by the probability of success produces a risk-adjusted expected cash flow. Some valuators bake probability into the discount rate instead; others apply it to the cash flows directly. The approach has to stay consistent so risk isn’t double-counted.
How IPR&D Is Carried After the Acquisition
Once fair value is determined, the acquirer records IPR&D as an intangible asset. ASC 350-30 then governs what happens next, and the key rule is this: acquired IPR&D is classified as an indefinite-lived intangible asset and is not amortized while the underlying project remains in progress.4Deloitte Accounting Research Tool. 4.4 Intangible Assets Not Subject to Amortization
The reasoning is that nobody knows how long the project will take or whether it will succeed. Setting an amortization schedule would require a useful life, and that estimate would be meaningless for something that might never become a product. So the asset sits on the balance sheet at acquisition-date fair value, neither growing nor shrinking through amortization, until its fate is resolved.
That treatment creates a temporary deferral of expense recognition. The acquirer has paid real consideration, but the income statement doesn’t feel the hit until the project either succeeds, triggering amortization, or fails, triggering a write-off. In acquisition-heavy companies, that can leave billions of dollars of IPR&D sitting on the balance sheet for years.
Impairment Testing and What Happens to the Project
Annual Testing
IPR&D isn’t amortized, but it isn’t ignored. ASC 350-30-35-18 requires annual impairment testing, or more frequent testing when events suggest the asset may have lost value. Triggering events include failed clinical trials, a competitor reaching market first, regulatory setbacks, or shifts in the commercial landscape that undermine expected returns.
The test compares the asset’s fair value to its carrying amount. If carrying value exceeds fair value, the company records an impairment loss equal to the difference, and it flows through the income statement as a component of income from continuing operations. The adjusted carrying amount becomes the new baseline. Impairment losses under GAAP are not reversed if circumstances later improve.
When the Project Succeeds
If the project reaches completion, usually marked by regulatory approval or the point where the product is ready for commercial use, the asset is reclassified from indefinite-lived to definite-lived. The company then assigns a useful life based on the expected period of economic benefit, often tied to the remaining patent life or anticipated product lifecycle, and begins systematic amortization.1U.S. Securities and Exchange Commission. 7. Intangible Assets That expense reduces reported earnings each period over the asset’s useful life.
When the Project Fails
If the project is abandoned or it becomes clear the technology will never reach commercial viability, the entire remaining carrying value is written off immediately. That produces a potentially large non-cash impairment charge in the period of abandonment. For companies that acquired multiple IPR&D projects in a single deal, a single project failure can materially depress quarterly earnings even though no cash leaves the building.
Investors should watch how companies handle these write-offs. Many exclude IPR&D impairment charges from their non-GAAP earnings metrics, presenting adjusted figures that strip the loss out. That isn’t inherently misleading, since the charge is non-cash and non-recurring, but it does mean GAAP earnings and the adjusted numbers management highlights can diverge sharply in the period of a write-off.
Tax Treatment Doesn’t Match the Accounting Treatment
One point of confusion worth separating out: the GAAP treatment described above and the federal tax treatment of acquired IPR&D are different, and treating them as the same is a common mistake. For tax purposes, IPR&D acquired in a business combination is generally treated as a Section 197 intangible, subject to straight-line amortization over 15 years regardless of whether the project is still in progress.5Office of the Law Revision Counsel. 26 U.S. Code 197 – Amortization of Goodwill and Certain Other Intangibles
The 15-year tax amortization begins when the asset is acquired, not when the project is completed. That creates a book-tax timing difference and generates a deferred tax liability on the GAAP balance sheet. The company gets tax deductions each year for the amortizing IPR&D, but under GAAP, no corresponding expense is recorded until the project succeeds or fails. Analysts tracking a company’s effective tax rate after a large acquisition should expect this divergence.